References
- Gray V, Kelly G, Xia M, et al. The science of USP 1 and 2 dissolution: present challenges and future relevance. Pharm Res. 2009;26:1289–1302.
- Al-Gousous J, Langguth P. Oral solid dosage form disintegration testing - the forgotten test. J Pharm Sci. 2015;104:2664–2675.
- Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, 1997.
- Japanese Pharmacopoeia (JP). Tokyo, Japan: Ministry of Health, Labour and Welfare; 2011.
- European Pharmacopoeia (PhEur). 8th Edition. Strasbourg, France: European Directorate for the Quality of Medicines, Council of Europe; 2014.
- The United States pharmacopeia. 37th revision. Rockville (MD): The United States Pharmacopoeial Convention; 2013.
- ICH Q6A guideline: Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances. International Conference on Harmonization; 2000.
- Gupta A, Hunt RL, Shah RB, et al. Disintegration of highly soluble immediate release tablets: a surrogate for dissolution. AAPS PharmSciTech. 2009;10:495–499.
- Han JH, Gallery J. A risk based approach to in vitro performance testing: A case study on the use of dissolution vs. disintegration for liquid filled soft gelatin capsules. Am Pharm Rev. 2006;9(5).
- Uebbing L, Klumpp L, Webster GK, et al. Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models. Drug Design Dev Ther. 2017;11:1163–1174.
- Nickerson B, Kong A, Gerst P, et al. Correlation of dissolution and disintegration results for an immediate-release tablet. J Pharm Biomed Anal. 2018;150:333–340.
- Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley and Sons; 1973.
- Trajenta (Linagliptin): assessment report. EMA/604444/2011. Committee for Medicinal Products for Human Use (CHMP); 23 June 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002110/WC500115748.pdf.
- Jardiance (Empagliflozin): assessment report. EMA/CHMP/137741/2014. Committee for Medicinal Products for Human Use (CHMP); 20 March 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf.
- Glund S, Mattheus M, Runge F, et al. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet. Int J Clin Pharmacol Ther. 2017;55:355–367.
- Sieger P, Cui Y, Scheuerer S. pH-dependent solubility and permeability profiles: a useful tool for prediction of oral bioavailability. Eur J Pharm Sci. 2017;105:82–90.